Sportradar Launches FanID Connecting Rightsholders and Brands with Sports Fans in a Post-Cookie World 16-01-2024, 15:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study 13-02-2023, 20:00